Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Researchers discover common genetic variants influence early puberty, body fat

Researchers at King's College London's Department of Twin Research have discovered, as part of a large international consortium, 30 new genes that control the age of sexual maturation in women, the Journal Nature Genetics publishes today.

22 Nov 2010

Inexpensive intervention helps patients with hypertension-associated kidney disease

In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines.

21 Nov 2010

Study finds gender difference in brain function of schizophrenics

Schizophrenia is a mental disorder that differs between the sexes in terms of age at onset, symptomatology, response to medication, and structural brain abnormalities. Now, a new study from the Universit- de Montr-al shows that there is gender difference between men and women's mental ability with women performing better than men.

20 Nov 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Antares advances VIBEX QS platform for highly-viscous drug injection

Antares Pharma, Inc., a leader in self-injection drug delivery technology, today announced the latest advancement in its proprietary line of VIBEX auto-injectors.

20 Nov 2010

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

While scientists depend on grants for their research, applying for them is a long and frequently frustrating process. For one Scripps Research Institute scientist, however, the process was shorter.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Health literacy leads to less hospitalization for heart failure

Being able to read and understand words like anemia, hormones and seizure means a patient with heart failure may be less likely to be hospitalized, according to a new study from Emory University School of Medicine. Findings will be presented Nov. 17 at the American Heart Association Scientific Sessions conference in Chicago.

18 Nov 2010

Study finds association between personality, cognitive ability and neuroendocrinal dysfunction in exhaustion syndrome

Exhaustion syndrome, also called burnout and exhaustion depression, leaves objectively measurable changes in the brain including reduced activity in the frontal lobes and altered regulation of the stress hormone cortisol. This is shown in a new dissertation from Umeå University in Sweden.

18 Nov 2010

Dim light at night linked to depression

Exposure to even dim light at night is enough to cause physical changes in the brains of hamsters that may be associated with depression, a new study shows.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death

From Roche Sequencing and Life Science 17 Nov 2010

New findings could help bypass unnecessary use of oxytocin in normal deliveries

It is standard practice in Swedish delivery rooms to use oxytocin to stimulate a labour that has been slow to start or has grind to a halt for a few hours. However, it is also fine to wait for a further three hours in first-time mothers, reveals a thesis from the University of Gothenburg, Sweden.

17 Nov 2010

Hormone News and Research

Further Reading

VYTORIN reduces major vascular events in patients with chronic kidney disease

Researchers discover common genetic variants influence early puberty, body fat

Inexpensive intervention helps patients with hypertension-associated kidney disease

Study finds gender difference in brain function of schizophrenics

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Discovery could provide new approaches to treat metabolic disorders

Merck wins third FOSAMAX bellwether trial

Antares advances VIBEX QS platform for highly-viscous drug injection

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

Study compares effect on HT status in mid, late life on dementia risk

Scientists solve receptor structure that responds to neurotransmitter dopamine

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Health literacy leads to less hospitalization for heart failure

Study finds association between personality, cognitive ability and neuroendocrinal dysfunction in exhaustion syndrome

Dim light at night linked to depression

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

NT-proBNP guided heart failure care associated with reduced cardiovascular events

New findings could help bypass unnecessary use of oxytocin in normal deliveries

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News